ABEONA THERAPEUTICS
Abeona Therapeutics is developing gene therapy-based potential cures for the deadly childhood diseases Sanfilippo (SF) Syndrome Type A and Type B. Its multi-platform expertise across the manufacture, delivery, development, and discovery of the novel gene and cell therapies has it uniquely positioned for success. Underpinning the Companyโs robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery.
ABEONA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Manufacturing Medical Device
Founded:
1989-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.abeonatherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
(216)287-5408
Email Addresses:
[email protected]
Total Funding:
274.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-12-19 | RF Wireless Solutions | RF Wireless Solutions acquired by Abeona Therapeutics | N/A |
Investors List
Jefferies
Jefferies investment in Post-IPO Equity - Abeona Therapeutics
H. C. Wainwright & Co.
H. C. Wainwright & Co. investment in Post-IPO Equity - Abeona Therapeutics
Maxim Group
Maxim Group investment in Post-IPO Equity - Abeona Therapeutics
FBR & Co
FBR & Co investment in Post-IPO Equity - Abeona Therapeutics
RBC Capital Markets
RBC Capital Markets investment in Post-IPO Equity - Abeona Therapeutics
Cantor Fitzgerald
Cantor Fitzgerald investment in Post-IPO Equity - Abeona Therapeutics
Stop Sanfilippo
Stop Sanfilippo investment in Grant - Abeona Therapeutics
George Soros
George Soros investment in Post-IPO Equity - Abeona Therapeutics
Key Employee Changes
Official Site Inspections
http://www.abeonatherapeutics.com Semrush global rank: 4.71 M Semrush visits lastest month: 2.02 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Abeona Therapeutics"
Abeona Therapeutics Inc. (ABEO)
Working together to deliver cell and gene therapies for people impacted by serious diseases Learn MoreSee details»
Company Information :: Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeonaโs lead clinical program is EB-101, its investigational โฆSee details»
Management Team :: Abeona Therapeutics Inc. (ABEO)
Previously, Mr. Vazzano served as Assistant Corporate Controller at Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) from October 2016 to July 2017, where he helped grow the finance and โฆSee details»
Abeona Therapeutics - Crunchbase Company Profile
Organization. Abeona Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Abeona Therapeutics develops gene therapy-based potential cures for โฆSee details»
Abeona Therapeutics Inc. (ABEO) Company Profile & Overview
4 days ago Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an โฆSee details»
Patients & Families :: Abeona Therapeutics Inc. (ABEO)
There are an estimated 7,000 rare diseases, each affecting fewer than 200,000 people in the U.S. These relatively small groups of patients collectively total more than 25 million Americans, but the breadth and devastation of rare disease is โฆSee details»
Abeona Therapeutics® Announces New Employee โฆ
5 days ago CLEVELAND, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity ...See details»
Abeona Therapeutics® Announces Appointment of Bernhardt โฆ
CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric โฆSee details»
Investor Relations :: Abeona Therapeutics Inc. (ABEO)
Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organizationโs Commercial Lead for CAR T-cell therapy programs. In this โฆSee details»
Abeona Therapeutics Announces FDA Accepts and Grants Priority โฆ
Nov 27, 2023 For more information, visit www.abeonatherapeutics.com. Forward-Looking Statements This press release contains certain statements that are forward-looking within the โฆSee details»
Abeona Therapeutics Inc. (ABEO) - Stock Analysis
5 days ago Website https://www.abeonatherapeutics.com. Full Company Profile. Financial Performance. In 2023, Abeona Therapeutics's revenue was $3.50 million, an increase of โฆSee details»
Clinical Trials :: Abeona Therapeutics Inc. (ABEO)
The US FDA expects to approve 10 to 20 gene therapies a year starting in 2025. [i] However, for any type of new medicine to be approved, it first must be proven to be safe and effective.See details»
Abeonatherapeutics Jobs, Employment | Indeed.com
The Scientific Director is a pivotal role within our organization, responsible for providing strategic scientific leadership and driving the advancement of pz-cel. Responsibilities: Provide โฆSee details»
Abeona Therapeutics - Craft
Oct 22, 2024 Dallas, TX HQ. United States. 3333 Lee Pkwy #600. Cleveland, OH. United States. 6555 Carnegie Ave 4th floor. New York, NY. United States. 1330 6th Ave 33rd FloorSee details»
Science :: Abeona Therapeutics Inc. (ABEO)
Our lead clinical program is pz-cel (prademagene zamikeracel, formerly EB-101), an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis โฆSee details»
Abeona Therapeutics® Announces FDA Acceptance of BLA โฆ
Nov 12, 2024 FDA assigns PDUFA target action date of April 29, 2025CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced โฆSee details»
Abeona Therapeutics Announces Leadership and Board Transitions
Sep 28, 2020 Investor Contact: Greg Gin VP, Investor Relations Abeona Therapeutics +1 (646) 813-4709 [email protected] Media Contact: Scott Santiamo Director, Corporate โฆSee details»
Abeona Therapeutics, Inc. (Abeona Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ โฆ
For more information, visit www.abeonatherapeutics.com. Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of โฆSee details»
Abeona Therapeutics® Reports Third Quarter 2024 Financial โฆ
Nov 14, 2024 For more information, visit www.abeonatherapeutics.com. Forward-Looking Statements This press release contains certain statements that are forward-looking within the โฆSee details»